1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non Small Cell Lung Cancer V.7.2021. © National Comprehensive Cancer Network Inc.2021. All rights reserved. Accessed October 29 2021. To view the most recent and complete version of the guideline go online toNCCN.org.
2. FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation–Positive Non–Small Cell Lung Cancer
3. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
4. U.S. Food & Drug Administration.FDA broadens afatinib indication to previously untreated metastatic NSCLC with other non‐resistant EGFR mutations.2018.https://www.fda.gov/drugs/resources‐information‐approved‐drugs/fda‐broadens‐afatinib‐indication‐previously‐untreated‐metastatic‐nsclc‐other‐non‐resistant‐egfr. Accessed May 1 2020.
5. U.S. Food & Drug Administration.FDA approves dacomitinib for metastatic non‐small cell lung cancer.2018.https://www.fda.gov/drugs/drug‐approvals‐and‐databases/fda‐approves‐dacomitinib‐metastatic‐non‐small‐cell‐lung‐cancer‐0. Accessed May 1 2020.